A Glimpse into FDA Perspectives: The Allogeneic Cell Therapy Searchlight Q&A
The Allogeneic Cell Therapy Searchlight recently hosted a pivotal FDA Q&A Session, steered by the insightful Peter Marks, Director of the Center for Biologics Evaluation and Research at the FDA. This engagement targeted urgent regulatory queries and offered an avenue for mutual understanding between the FDA and the industry. A significant goal was to pave…Read more
Read MoreAllogeneic Cell Therapy Searchlight: Scalable Manufacturing Initiative in Focus
Under the expert guidance of Dr. Marta Barisa and Evren Alici, the Allogeneic Cell Therapy Searchlight network recently convened for a workshop. The focus was sharp: delving into the pressing challenges and evolving strategies in the sphere of scalable manufacturing. Aimed at pinpointing the obstacles in the allogeneic cell therapy landscape, this pivotal session marked…Read more
Read MoreA Revolution in Treating Multiple Myeloma: Anti-BCMA CAR-Based Immune Cell Therapies
A Glimpse at the Current Landscape Multiple Myeloma (MM) is the second most common blood cancer. It’s characterized by the build-up of harmful plasma cells in the bone marrow. As of 2016, MM cases have surged by 126% since 1990, affecting hundreds of thousands globally. Thankfully, advancements in treatments have led to improved survival rates.…Read more
Read MoreUnlocking the Power of Cytokines in Allogeneic Cell Therapies
A New Paradigm in Cell Therapies The world of cell therapy is buzzing, and a groundbreaking paper authored by Chen-Yuan Kao, Jason A. Mills, Carl J. Burke, Barry Morse, and Bruno F. Marques shines light on an integral component: cytokines. Their study, titled ‘Role of Cytokines and Growth Factors in the Manufacturing of iPSC-Derived Allogeneic…Read more
Read MoreAllogeneic Cell Therapy: From Origins to Future Innovations
The Genesis of Allogeneic Cell Therapy: When it comes to cancer treatment, allogeneic cell therapy is nothing short of revolutionary. Stemming from the concept of hematopoietic stem cell transplantation presented 60 years ago, it opened doors to innovative treatments for various diseases, especially leukemia. However, challenges arose, like graft versus host disease (GVHD) and regimen-related…Read more
Read MoreUnlocking the Potential: Natural Killer Cells in Cancer Therapy
Introducing Allogeneic Natural Killer Cell Therapy Melissa M. Berrien-Elliott, Miriam T. Jacobs, and Todd A. Fehniger present a deep dive into the medical community’s exploration against cancer with their paper on ‘Allogeneic natural killer cell therapy’. As the race to find more effective cancer treatments continues, this paper brings to light the potential of…Read more
Read More